Sotyktu – Talk Bio

Actionable Insights Powered by AI

Sotyktu Shows Promise in Phase 3 Psoriatic Arthritis Trial

1 month ago talkbio0Tagged Arthritis, Psoriatic, deucravacitinib, Inhibitor, Myers, POETYK, PsA-2 trial, Sotyktu, squibb, TYK2 gene

Sotyktu, deucravacitinib, psoriatic arthritis, Bristol Myers Squibb, POETYK PsA-2 trial, TYK2 inhibitor

Sotyktu Expands Potential with Successful Phase III Trials in Psoriatic Arthritis

4 months ago talkbio0Tagged Arthritis, Psoriatic, deucravacitinib, Inhibitor, Myers, Phase 3 Clinical Trials, Sotyktu, squibb, TYK2 gene

Sotyktu, deucravacitinib, psoriatic arthritis, Phase III trials, Bristol Myers Squibb, TYK2 inhibitor

Top 10 Pharmaceutical Drug Ad Spenders: A Review of the Latest Rankings

11 months ago talkbio0Tagged AbbVie, Caplyta, Drugs, Non-Prescription, Dupixent, Jardiance, Opdivo, Rexulti, Rinvoq, Sotyktu, Vraylar

pharmaceutical drug ad spenders, top 10, AbbVie, Skyrizi, Rexulti, Dupixent, Rinvoq, Vraylar, Sotyktu, Jardiance, Ozempic, Caplyta, Opdivo